Mantle cell lymphoma (MCL) is a clinically aggressive B-cell non-Hodgkin lymphoma characterized by the t(11;14)(q13;q32) and overexpression of cyclin D1. A high proportion of MCL tumors harbor wild-type (wt) and potentially functional p53 gene. We show here that stabilization and activation of wt-p53 using a recently developed potent MDM2 inhibitor, nutlin 3A, results in significant p53-dependent G1-S cell cycle arrest and apoptosis in MCL cells through regulation of p53 target genes. As mTOR signaling is activated in MCL and may control cyclin D1 levels, we show that p53 activation may downregulate the AKT/mTOR pathway through a mechanism involving AMP kinase (AMPK). Despite the non-genotoxic mode of nutlin 3A treatment, we show evidence that stabilization of p53 is associated with its phosphorylation at serine 15 residue and activation of AMPK. Stimulation of AMPK kinase activity using AICAR inhibits phosphorylation of critical downstream effectors of mTOR signaling, such as 4E-BP1 and rpS6. Pharmacologic inhibition of AMPK using compound C in nutlin-3A-treated MCL cells harboring wt-p53 did not affect the level of ser15 p-p53, suggesting that the ser15 p-p53-AMPK is the direction involved in the p53/AMPK/mTOR cross talk. These data establish a p53-AMPK-mTOR mechanism in MCL and uncover a novel biologic effect of potent MDM2 inhibitors in preclinical models of MCL.
Introduction
Studies using genetically manipulated animal models have proved the biologic significance of the p53 tumor suppressor pathway for the maintenance of established tumors. [1] [2] [3] The importance of the AKT/mTOR pathway in the development and chemoresistance of malignancies including lymphomas is also well established. 4, 5 Although defects in the p53 or AKT/mTOR pathways occur in most human cancers, coexistent defects are quite uncommon suggesting a possible link between these two pathways. 6 Mantle cell lymphoma (MCL) is an aggressive type of B-cell non-Hodgkin lymphoma characterized by cyclin D1 overexpression as a result of the t(11;14)(q13;q32). 7 Defects in the p53 pathway have been reported in MCL; however, a high proportion of MCL tumors carry wild-type (wt) p53 gene. In addition, we recently showed that activation of mTOR signaling contributes to cell cycle and apoptosis deregulation in MCL and controls cyclin D1 expression. 8 The levels and activity of p53 in mammalian cells are critically regulated by its physiologic inhibitor, MDM2 (HDM2 in humans). 9 Nutlin-3A, a recently developed small molecule that disrupts the MDM2-p53 interaction stabilizing and activating p53 protein, has substantial in vitro and in vivo antitumor activity against cancer including hematologic malignancies. [10] [11] [12] [13] [14] We show in a preclinical MCL model that activation of functional p53 pathway leads to p53-dependent cell cycle arrest and apoptosis, providing a potential therapeutic strategy in patients with MCL. This study also uncovers a novel function of nutlin-3A-induced activation of p53, thus establishing for the first time in human lymphoma cells a p53-AMPK-mTOR cross-talk mechanism.
Materials and methods

Cell lines and reagents
Six MCL cell lines, Jeko-1, Mino, SP-53 (classic MCL), Granta-519, 15 M-1 and Z-138 (blastoid variant MCL), were cultured under standard conditions as previously described. 8 Nutlin-3A (Sigma, St Louis, MO, USA), the AMP kinase (AMPK) stimulator AICAR, and the AMPK inhibitor compound C (Calbiochem, San Diego, CA, USA) were used at various concentrations and time points as indicated. MDM2-p53 interaction was inhibited using a racemic mixture of the active and inactive enantiomers, nutlin-3A and nutlin-3B (Sigma), respectively. In all experiments the indicated concentrations refer to the active component nutlin-3A.
Detection of p53 mutations
Total RNA extraction, synthesis of cDNA, amplification of the entire open reading frame of p53 gene by PCR and sequencing were performed as previously described.
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Western blot analysis and immunoprecipitation p53, Ser15 phosphorylated (p)-p53, p21, MDM2, BAX, BCL2, PUMA, BCL-XL, activated caspase-3, Ser473 p-AKT, total AKT, p-p70S6 K, p70S6 K, p-rpS6, rpS6, p-4E-BP1, 4E-BP1, eIF4E, cyclin D1, AMPK, Thr172 p-AMPK and b-actin protein levels were assessed by western blot analysis as described.
8 Ser15 p-p53 blocking peptide (Cell Signaling, Danvers, MA, USA), phosphatase inhibitors (Sigma) or alkaline phosphatase enzyme (Roche Diagnostics, Indianapolis, IN, USA) were used at appropriate concentrations as indicated.
Immunoprecipitation of whole cell lysates using anti-p70S6K antibody was performed as previously described. 16 p70S6K activity p70S6K activity was determined using the p70S6 kinase assay kit purchased by Upstate (Charlottesville, VA, USA), according to the manufacturer's instructions. Briefly, activity was assayed in total p70S6K immunoprecipitates in a final volume of 50 ml containing 50 mM S6-substrate peptide-2 and 200 mmol/l [g-32 P]ATP. The phosphate incorporation was measured by liquid scintillation counting.
Cell viability and proliferation studies
Cell viability was assessed using Trypan blue exclusion cell counts in triplicate. 8 Cell proliferation was evaluated using a tetrazolium compound [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolioum, MTS], the CellTiter 96 aqueous cell proliferation assay (Promega, Madison, WI, USA) and mQuant spectrophotometer (BIO-TEK Instruments Inc., Winooski, VT, USA) according to the manufacturer's protocol. All experiments were repeated at least three times.
Cell cycle and apoptosis analysis
Cell cycle and apoptosis were assessed using propidium iodide and annexin-V staining (BD Biosciences Pharmingen, San Diego, CA, USA), respectively, analyzed by flow cytometry. 8 Apoptotic morphology was evaluated by DAPI staining and fluorescence microscopy. 8 All experiments were repeated at least three times.
Results
Nutlin-3A induces cell cycle arrest in MCL cells through stabilization of p53 and upregulation of p21 p53 mutation analysis showed that Jeko-1 cells carry a STOP codon located at codon 122-123 (exon 4) because of a single C nucleotide deletion at codon 58 17 and Mino have a singlenucleotide substitution [440 T-G] changing valine for glycine at codon 147 of exon 5. 18 Granta 519, M-1, SP-53 and Z-138 were found to carry wt-p53 gene. This is the first characterization of p53 gene status in Z-138 and M-1. At 24 h after treatment with 5 mM nutlin-3a, the S-phase fraction decreased by 73, 40, 39 and 35%, in Granta 519, M-1, SP-53 and Z-138, respectively, with a concomitant concentration-dependent increase in G1-phase, indicating G 1 -S phase cell cycle arrest. No effect on the cell cycle was observed in MCL cell lines with mutated (mt)-p53 gene (Figure 1a) .
Western blot analysis showed a dose-dependent increase in p21 levels, parallel with the increase in p53 and MDM2 levels, specifically in MCL cells harboring wt-p53 gene at 24 h after treatment with nutlin-3A. Data for the M-1, SP-53 (wt-p53), Mino and Jeko-1 (mt-p53) cell lines are shown ( Figure 1b ).
Nutlin-3A induces apoptotic cell death in MCL cells through activation of the p53 apoptotic pathway Western blot analysis showed a slight increase in the expression level of the proapototic proteins BAX and PUMA in all MCL cells harboring wt-p53, 24 h after treatment with 5 mM nutlin-3A. In addition, M-1 cells showed a slight decrease in the expression level of the antiapoptotic protein BCL2, while Granta-519, SP-53 and Z-138 showed a slight decrease of the antiapoptotic protein BCL-XL. Western blot analysis also showed cleavage of caspase-3. Although a dramatic increase of apoptosis was observed at 48 h after treatment, apoptotic death was already initiated at 24 h following nutlin-3A treatment ( Figure 2b ). Similar changes were not observed in the nutlin-3A-treated, Jeko-1 and Mino cells harboring mutated p53 gene ( Figure 2b ).
Microscopic examination of the DAPI-stained cell preparations at 24 or 48 h after treatment with 5 mM nutlin-3A showed morphologic evidence of apoptosis, including nuclear condensation and fragmentation (apoptotic bodiesFarrows) in cultured MCL cells harboring wt-p53 (Figure 2b ).
Nutlin-3A downregulates the mTOR oncogenic pathway in MCL
To investigate the effects of p53 stabilization and activation on AKT/mTOR signaling, whole cell lysates of MCL cells were prepared at 24 h after treatment with increasing concentrations of nutlin-3A, and the phosphorylation (activation) status of AKT/ mTOR signaling proteins was assessed by western blot analysis. Immunoblots showed decreased phosphorylation of rpS6 and 4E-BP1 following nutlin-3A treatment (Figure 3a) . The levels of total eIF4E protein remained constant in SP-53 and Granta 519 but were decreased in M-1. Additionally, AKT phosphorylation ( Ser473 p-AKT), known to be regulated by mTOR-Rictor complex, was also decreased by nutlin-3A (Figure 3a) . No similar changes were observed in the p53-mutated cell lines Jeko-1 and Mino following nutlin 3a treatment.
Treatment of MCL cells harboring wt-p53 with nutlin-3A resulted in decreased threonine-389 phosphorylation of p70S6K as shown by western blot of thr389 p-p70S6K1 (Figure 3b ). Furthermore, p70S6K enzymatic activity assessed using a radioactive kinase assay in whole protein lysates of SP-53 and Granta 519 cells was substantially reduced at 24 h after nutlin-3A treatment (Figure 3b ).
AMPK activation contributes to mTOR regulation in MCL cells
In a previously proposed model, serine-phosphorylated (activated) p53 is capable of inducing AMPK activation through a still unknown exact mechanism, which, in turn, results in mTOR downregulation. 6 To test this model, we first investigated whether AMPK activation contributes to downregulation of the mTOR pathway in MCL cells. AMPK was stimulated with increasing concentrations of the AMP analog AICAR. This resulted in AMPK phosphorylation (activation), which was associated with decreased levels of phosphorylated rpS6 and 4E-BP1 at 24 h after treatment with AICAR in MCL cells (Figure 4a ). Consequently, we assessed the effects of nutlin-3A-induced p53 stabilization and activation on AMPK activation status.
After 24 h treatment with 10 mM nutlin-3A, activation (phosphorylation) of AMPK was detected in MCL cells harboring wt-p53 gene (Figure 4b ). Of note, increased levels of phosphorylated AMPK ( thr172 p-AMPK) induced by nutlin-3A treatment were associated with increased levels of ser15 p-p53. These results Most previous studies on nutlin-3A treatment of cancer cells have shown no significant nutlin-3A-induced serine phosphorylation of p53 ( ser15 p-p53). To further test the specificity of the antiser15 p-p53 antibody used in this study, experiments were performed using a ser15 p-p53-specific blocking peptide and alkaline phosphatase treatment. Pre-incubation of the antiser15 p-p53 antibody with 100 mM of the peptide or treatment of the lysates with alkaline phosphatase (0.5 U/1 mg target protein) in the absence of phosphatase inhibitors abolished the ser15 p-p53 signal in M-1 or SP-53 cells treated for 24 h with 10 mM nutlin-3a (Figure 4c) .
Also, protein lysates of M-1 and Granta 519 cells were prepared after treatment with 10 mM compound C, an AMPK inhibitor, for 8 h and sequentially for 20 h with 10 mM nutlin-3a. Pharmacologic inhibition of AMPK in nutlin-3A-treated MCL cells harboring wt-p53 did not affect the level of ser15 p-p53, suggesting that the ser15 p-p53-AMPK is the direction involved in the p53/AMPK/mTOR cross talk (Figure 4d ).
Discussion
We show that inhibition of p53-MDM2 interaction stabilizes p53 and leads to p53-dependent cell cycle arrest and apoptosis in MCL cells that carry wt-p53. Using MCL in an in vitro system, this study also uncovers a novel cross talk mechanism between p53, AMPK and mTOR pathways in human lymphomas. Downregulation of the AKT/mTOR oncogenic pathway by activated p53 is important for MCL in light of the role of AKT/mTOR signaling in maintaining tumor cell survival and proliferation. 8 The p53 gene mutation status of MCL cell lines invariably predicted sensitivity to nutlin-3a. Treatment with nutlin-3A resulted in G 1 -S cell cycle arrest only in MCL cell lines expressing wt-p53. Cell cycle changes were accompanied by p53 protein stabilization and upregulation of its transcriptional targets MDM2 and p21. 10 Although p53 mutation status is an absolute criterion in predicting the nutlin-3A-induced cell cycle effects, this might not hold true regarding apoptotic effects, probably because of downstream defects in the p53 pathway. 
In this study, nutlin-3A treatment induced significant apoptotic cell death, associated with cleavage of caspase-3, upregulation of the proapoptotic proteins BAX and PUMA (both transcriptional targets of p53) and slight decrease of the antiapoptotic protein BCL-XL in all MCL cells harboring wt-p53. Defects in the p53 pathway other than p53 mutations have been reported in MCL. These defects mostly operate upstream of p53 and include overexpression of MDM2, or inactivation of the p14 ARF or ATM genes. 7 For instance, homozygous deletion of the INK4a/ARF locus has been reported in Z-138 and Granta 519, which carry wt-p53 gene. 17, 19 This preferential accumulation of defects upstream of p53 implies that the pathway downstream of p53 frequently preserves its functional integrity in MCL. Interestingly, homozygous deletion of the BH3-only proapoptotic gene BIM recently reported in SP-53 and Z-138 (wt-p53) does not seem to affect the apoptotic machinery activated by nutlin-3A-induced p53. 19 Recently, a novel link between the p53 and mTOR pathways has been proposed, although the precise underlying mechanisms are not fully understood. 6 We have shown that mTOR signaling is activated in MCL and may control translation of cyclin D1 protein. 8 We found that stabilized and active wt-p53 protein dephosphorylates 4E-BP1, p70S6K and ribosomal protein S6 (p-rpS6), 8, 20 important regulatory components of the translational machinery, in MCL cells. Notably, nutlin-3A treatment was associated with decreased cyclin D1 expression confirming our published data showing control of cyclin D1 by mTOR and eIF4E in MCL. 8 Furthermore, decreased levels of activated AKT ( ser473 p-AKT), known to be regulated by mTORRictor complex, were observed. p53/mTOR cross talk in mantle cell lymphoma E Drakos et al AMPK is sensitive to energy status and conveys signals to the mTOR pathway by phosphorylating and activating the tuberous sclerosis complex 2 protein. AMPK has been proposed to be involved in communication between the p53 and mTOR pathways. 6 We found that p53 activation resulted in AMPK phosphorylation ( thr172 p-AMPK). Moreover, treatment with the AMP analog AICAR downregulated the mTOR pathway in MCL cells. Taken together, these data suggest that AMPK mediates, at least in part, the effects of p53 on mTOR in MCL. Because earlier studies that linked p53 to the mTOR pathway through AMPK used mostly genotoxic activation of p53 in their experiments, and nutlin-3A activates p53 by a non-genotoxic mechanism, we also investigated the phosphorylation status of p53 in our in vitro system. 6, 10 To our surprise, we found a significant increase in ser15 p-p53 levels in all MCL cells treated with nutlin-3A. To our knowledge, similar findings have been reported only by Secchiero et al. 22 in chronic lymphocytic leukemia and their significance remains uknown. Although the high levels of ser15 p-p53 detected after nutlin-3A treatment may represent increased induction of p53 phosphorylation by aFstill unknownFmechanism, one cannot exclude the possibility of increased rate of previously phosphorylated p53, as the total p53 levels are dramatically increased as well.
As earlier studies have shown that a reverse pathway in which activated AMPK induces phosphorylation of p53 at serine 15 residue may also exist, 23 AMPK activity was selectively inhibited using compound C in nutlin-3A-treated MCL cells. Inhibition of AMPK activity was not associated with downregulation of ser15 p-p53 in nutlin-3A-treated cells, suggesting that p53 actually induces AMPK activation and the opposite is not true in MCL. A recent study reported multiple transcriptional targets of p53 that are components of the mTOR pathway, including AMPK, in other cell types. 24 These data further support our hypothesis.
To our knowledge, this is the first study to establish an active p53-AMPK-mTOR link in human lymphomas. As p53 is likely to be functional in most MCL patients, and activation of the mTOR pathway plays an important role in proliferation and survival of MCL cells, targeted inhibition of p53-MDM2 interaction appears to be a promising therapeutic strategy for these patients.
